Earlier, in September 2016, Novartis had bought back 3.82 million shares of the company at a price of Rs 760 per share.
Thus far in the calendar year 2017, the stock has underperformed the market by falling 24% as compared to 22% rise in the S&P BSE Sensex till Wednesday.
At 9:37 am, the stock was up 5% at Rs 679 against 0.09% rise in the benchmark index. The trading volumes on the counter jumped an over seven-fold. Around 79,000 shares changed hands on BSE against an average 11,000 shares were traded in past two weeks.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)